NIH R01 · 2024
Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study
Project Summary There is an urgent need for agents that slow or arrest the progressive course of AD. BAN2401 and aducanumab, antibodies partially targeting soluble Aβ oligomers, have shown efficacy in late-stage clinical trials, validating amyloid targeting in AD. ALZ-801, an oral agent that selectively inhibits the formation of Aβ oligomers, is an improved prodrug formulation of tramiprosate. ALZ-801 and its active agent, tramiprosate, showed favorable preclinical and clinical safety that supports a regulatory submission. Alzheon is developing ALZ-801 as a disease-modifying treatment for AD patients who are homozygous for the ε4 allele of the apolipoprotein E gene (APOE4). Tramiprosate was…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.